for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

U.S. district court rules for Mylan in MS drug patent battle with Biogen

June 18 (Reuters) - A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc’s blockbuster multiple sclerosis drug Tecfidera, sending the drugmaker’s shares down 7%.

The ruling comes months after the U.S. Court of Appeals for the Federal Circuit ruled that a bioequivalent version of Tecfidera made by Banner Life Sciences LLC does not infringe a Biogen patent that was set to expire in June.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up